Karam Maroun, Roberts-Klein Shayna, Shet Narendra, Chang Johanna, Feustel Paul
Nuclear Medicine Section, Radiology Department, Albany Medical College, Albany, New York 12208, USA.
J Nucl Med. 2008 Sep;49(9):1429-36. doi: 10.2967/jnumed.107.048983.
Bilateral hilar (18)F-FDG-avid foci are often noted on PET studies of patients without lung cancer. This finding may lead to diagnostic uncertainty about the presence of metastatic disease. Our objective was to evaluate features of these foci associated with benign or malignant etiology.
We performed a retrospective study of patients with cancer with bilateral hilar foci on 1 or 2 sequential (18)F-FDG PET studies between 2002 and 2006. Patients with lung cancer, sarcoidosis, or anthracosis/silicosis were excluded. Variables evaluated were maximum standard uptake values (SUV max), purity (absence of (18)F-FDG-avid foci in nonhilar mediastinal nodes), symmetry (difference between left and right side SUV max), the primary tumor, node size determined by CT, and, in those who participated in 2 studies, stability of uptake over time. The gold standard was histologic diagnosis or long-term clinical follow-up (range, 19-41 mo; mean, 25 mo).
Fifty-one patients with the finding of bilateral hilar (18)F-FDG-avid foci underwent a staging-only PET study; 52 scans from an additional set of patients demonstrated this abnormality on at least 1 of 2 sequential studies, the first of which was performed for staging. On univariate analysis, variables associated with malignancy were SUV max (6.6+/-4.1 vs. 3.5+/-1.0 for benign, P<0.001; t test); impurity (P<0.001; chi(2) test), with 79% of impure scans versus 18% of pure scans being malignant; node size determined by CT (P=0.027); and change in uptake between scans 1 and 2 (change in SUV=2.7+/-2.1 vs. 0.73+/-1.1 for benign, P < 0.01; t test). Variables associated with benign etiology were: symmetry (difference between left and right sides=0.57+/-0.54 for benign vs. 1.8+/-1.7 for malignant, P<0.01), purity, and colorectal primary (75% of colorectal were benign vs. 34% of breast, 49% of lymphoma, and 37% of other, P=0.030; chi(2) test). After multivariate analysis, SUV max and purity were found to be independent predictors, with the odds of malignancy increasing by 1.54 (95% confidence interval, 1.16-2.05) for each unit increase in SUV and decreasing by 0.08 (95% confidence interval, 0.03-0.22) if pure.
In patients with nonlung cancer, in particular colorectal, foci of symmetric and mild uptake limited to the hilar regions that are stable on 2 sequential PET studies despite intervening anticancer therapy are likely related to a benign etiology.
在无肺癌患者的PET研究中,经常会发现双侧肺门(18)F - FDG摄取灶。这一发现可能导致对转移性疾病存在与否的诊断不确定性。我们的目的是评估这些病灶与良性或恶性病因相关的特征。
我们对2002年至2006年间在1次或2次连续的(18)F - FDG PET研究中出现双侧肺门病灶的癌症患者进行了一项回顾性研究。排除肺癌、结节病或炭末沉着症/矽肺患者。评估的变量包括最大标准摄取值(SUV max)、纯度(非肺门纵隔淋巴结中无(18)F - FDG摄取灶)、对称性(左右侧SUV max的差异)、原发肿瘤、CT确定的淋巴结大小,以及在参与2项研究的患者中,摄取随时间的稳定性。金标准是组织学诊断或长期临床随访(范围为19 - 41个月;平均为25个月)。
51例发现双侧肺门(18)F - FDG摄取灶的患者仅接受了分期PET研究;另外一组患者的52次扫描在2次连续研究中的至少1次中显示了这种异常,其中第一次扫描是用于分期。单因素分析显示,与恶性相关的变量有:SUV max(良性为6.6±4.1,恶性为3.5±1.0,P<0.001;t检验);不纯性(P<0.001;卡方检验),79%的不纯扫描为恶性,而纯扫描为恶性的比例为18%;CT确定的淋巴结大小(P = 0.027);以及扫描1和扫描2之间摄取的变化(SUV变化:良性为2.7±2.1,恶性为0.73±1.1,P < 0.01;t检验)。与良性病因相关的变量有:对称性(左右侧差异:良性为0.57±0.54,恶性为1.8±1.7,P<0.01)、纯度以及结直肠原发肿瘤(75%的结直肠癌为良性,而乳腺癌为34%,淋巴瘤为49%,其他为37%,P = 0.030;卡方检验)。多因素分析后发现,SUV max和纯度是独立的预测因素,SUV每增加1个单位,恶性的几率增加1.54(95%置信区间,1.16 - 2.05),如果是纯的则降低0.08(95%置信区间,0.03 - 0.22)。
在非肺癌患者中,特别是结直肠癌患者,尽管进行了抗癌治疗,但在2次连续PET研究中局限于肺门区域的对称且轻度摄取的病灶在2次连续PET研究中稳定,可能与良性病因有关。